Replies to post #552527 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Glioblastoma is highly heterogeneous. In the trial, the vaccine was manufactured from the tumor tissue of the first surgery. Imagine what would happen if the vaccine were updated with the tissue from the recurrent tumor. Without a doubt, the results should be even better.

[Horseb4CarT]

LL was adding up the long lived from the several groups and was at about 50 with just the first two groups, then she was adding another set so that is why I said >50.

The SOC only patients don’t survive past 5 years, and if that is wrong by 1 or 2 it doesn’t change the comparison significantly nor the decision of which provides the best outcome.

Seems crystal clear to those closest to nGBM and rGBM, like the neurosurgeons who treat these patients and haven’t been able to offer much hope for longer term survival.